On 1 March, at the end of the 13th WTO Ministerial Conference, IFPMA issued a statement.
Read moreAs discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
On 23 February, ahead of the 13th WTO Ministerial Conference, IFPMA and member associations from 10 countries issued a joint statement calling on trade ministers to commit to a comprehensive trade and health agenda that will strengthen the innovation ecosystem, remove trade barriers, promote trade facilitation, strengthen regulatory systems, and address under-resourced healthcare infrastructure.
Read moreOn 23 February 2024, IFPMA submitted a statement at the Joint Plenary Meeting of the Intergovernmental Negotiating Body (INB) and the Working Group on the Amendments to the International Health Regulations (2005) (WGIHR) in Geneva, Switzerland.
Read moreOn 19 February in Geneva, Switzerland, IFPMA delivered a statement at the 8th Meeting of the Intergovernmental Negotiating Body (INB).
Read moreThis position paper outlines some key regulatory agilities implemented in areas such as research and development, regulatory evaluations, authorizations, and post-approval changes (PACs) and labelling. Key learnings and recommendations to enhance regulatory frameworks in the future are also included.
Read more
The fourth meeting of the WHO’s Fair Pricing Forum represents an important opportunity to discuss how the global health community can work together to improve access to medicines and vaccines, deliver on the ambition of the Sustainable Development Goals (SDGs), and to achieve Universal Health Coverage (UHC) by 2030. IFPMA and our members continue to be committed to these goals and welcome the opportunity to share perspectives on how we can work together to achieve them.
Read moreOn 5 February, IFPMA delivered a statement at the 7th Meeting of the Working Group on Amendments to the International Health Regulations (2005) in Geneva, Switzerland.
Read moreMedical breakthroughs provide hope to patients, families and caregivers all over the world. However, we know that these ground-breaking advances in healthcare are only meaningful when they can reach the people who need them. To be successful, we need to be as innovative in our approaches to patient access as we are in the scientific discovery and development of medicines and vaccines themselves.
Read more
Regulatory agility played a crucial role in speeding up the development and approval of medicines and vaccines during the COVID-19 pandemic. The insights gained from this success are valuable for continually strengthening regulatory frameworks, both in emergency and non-emergency situations. IFPMA collaborated with external researchers to gather insights from national regulatory authorities and pharmaceutical companies on the success factors behind regulatory agility, especially ahead of future pandemics.
Read more
This report aims to explore the perspective of members of NRAs on the use of regulatory agilities which emerged during the COVID-19 pandemic and describe lessons learnt from this experience.
Read more
On 24 January, IFPMA delivered a statement on antimicrobial resistance (AMR) at the WHO 154th Executive Board in Geneva, Switzerland.
Read more